Small, struggling biotech winds up with a 3X loser as another PhIII of its lead drug collapses

Little Tonix Pharmaceuticals has run into another brick wall as its lead drug — a reformulated muscle relaxant originally approved 44 years ago — has failed another Phase III study, sending shares back into penny stock territory.